Autolus Therapeutics plc - American Depositary Share (AUTL): Price and Financial Metrics

Autolus Therapeutics plc - American Depositary Share (AUTL)

Today's Latest Price: $13.44 USD

0.84 (-5.88%)

Updated Sep 21 6:55pm

Add AUTL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

AUTL Stock Summary

  • AUTL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.19 -- higher than merely 4.44% of US-listed equities with positive expected earnings growth.
  • AUTL's price/sales ratio is 488.74; that's higher than the P/S ratio of 98.89% of US stocks.
  • As for revenue growth, note that AUTL's revenue has grown -57.46% over the past 12 months; that beats the revenue growth of only 3.1% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Autolus Therapeutics plc are ASND, CRNX, FATE, QURE, and OTIC.
  • Visit AUTL's SEC page to see the company's official filings. To visit the company's web site, go to
AUTL Daily Price Range
AUTL 52-Week Price Range

AUTL Stock Price Chart Technical Analysis Charts

AUTL Price/Volume Stats

Current price $13.44 52-week high $17.19
Prev. close $14.28 52-week low $3.00
Day low $13.17 Volume 119,000
Day high $14.22 Avg. volume 179,087
50-day MA $14.66 Dividend yield N/A
200-day MA $11.80 Market Cap 604.57M

Autolus Therapeutics plc - American Depositary Share (AUTL) Company Bio

Autolus Therapeutics is developing a pipeline of advanced programmable T cell treatment candidates for blood and solid tumor cancers. Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I), or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma. The company is based in London, England.

AUTL Latest News Stream

Event/Time News Detail
Loading, please wait...

AUTL Latest Social Stream

Loading social stream, please wait...

View Full AUTL Social Stream

Latest AUTL News From Around the Web

Below are the latest news stories about Autolus Therapeutics plc that investors may wish to consider to help them evaluate AUTL as an investment opportunity.

Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September

LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO3 data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and to participate in Banking conferences through September: * 9 September 2020 – The company will participate in an analyst moderated group meeting at the Wells Fargo Virtual Healthcare Conference at 9.20 am EDT, 2.20 pm BST and will also host virtual one-on-one meetings. A live audio webcast of the fireside chat will be available on the investor relations section of the Company’s website at Autolus. An archived replay will be ava...

Yahoo | September 8, 2020

Can You Imagine How Autolus Therapeutics' (NASDAQ:AUTL) Shareholders Feel About The 47% Share Price Increase?

If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...

Yahoo | September 1, 2020

Autolus Therapeutics PLC (AUTL) CEO Christian Itin on Q2 2020 Results - Earnings Call Transcript

Autolus Therapeutics PLC (AUTL) Q2 2020 Earnings Conference Call August 06, 2020, 08:30 ET Company Participants Lucinda Crabtree - VP, IR & Corporate Communications Christian Itin - Chairman & CEO Andrew Oakley - CFO & SVP Conference Call Participants Mara Goldstein - Mizuho Securities Biren Amin - Jefferies Eric Joseph...

SA Transcripts on Seeking Alpha | August 9, 2020

Autolus Therapeutics plc 2020 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2020 Q2 earnings call....

SA Transcripts on Seeking Alpha | August 7, 2020

J.P. Morgan: These 2 Healthcare Stocks Are Must-Watch Names

Marching forward together, the previous decade saw equities and bonds rally right alongside each other. At the same time, there was a negative correlation of daily returns, limiting portfolio volatility. This was a good thing for multi-asset portfolios like pension funds which benefited from the high-low frequency correlation, with declining yields also giving a bump to specific equity market sectors.Today, things have changed, with bond yields landing at almost zero. According to J.P. Morgan strategist Marko Kolanovic, this implies that the trend might be fading away, which poses a major threat to multi-asset portfolios.“Should yields (or inflation expectations) start rising, these portfolios could experience a triple-whammy: bond values would go lower, valuations of the above-describe...

Yahoo | August 5, 2020

Read More 'AUTL' Stories Here

AUTL Price Returns

1-mo -14.50%
3-mo -14.23%
6-mo 139.15%
1-year 2.83%
3-year N/A
5-year N/A
YTD 1.82%
2019 -59.81%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6833 seconds.